{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:07:13Z","timestamp":1782961633800,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2022A1515011312"],"award-info":[{"award-number":["2022A1515011312"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Special Projects in Key Areas of Colleges and Universities in Guangdong Province","award":["2022ZDZX2015"],"award-info":[{"award-number":["2022ZDZX2015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-024-04671-3","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:34:55Z","timestamp":1731072895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect and mechanisms of shikonin on breast cancer cells in vitro and in vivo"],"prefix":"10.1186","volume":"24","author":[{"given":"Chuyi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaguo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjia","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"issue":"3","key":"4671_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4671_CR2","doi-asserted-by":"crossref","unstructured":"Dass SA, Tan KL, Rajan RS et al. Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities[J]. Medicina (Kaunas, Lithuania), 2021, 57(1):62.","DOI":"10.3390\/medicina57010062"},{"issue":"1","key":"4671_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer[J]. J Hematol Oncol. 2022;15(1):121.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4671_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res. 2020;22(1):61.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"4671_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12032-021-01610-x","volume":"39","author":"A Nath","year":"2021","unstructured":"Nath A, Mitra S, Mistry T, et al. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer[J]. Med Onco. 2021;39(1):14.","journal-title":"Med Onco"},{"key":"4671_CR6","doi-asserted-by":"crossref","unstructured":"He MY, Chlo\u00e9, Rancoule A, Rehailia-Blanchard et al. Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies[J]. Critical Reviews in Oncology\/Hematology, 2018, 131: 96\u2013101.","DOI":"10.1016\/j.critrevonc.2018.09.004"},{"issue":"1","key":"4671_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, et al. Advances in immunotherapy for triple-negative breast cancer[J]. Mol Cancer. 2023;22(1):145.","journal-title":"Mol Cancer"},{"issue":"23","key":"4671_CR8","doi-asserted-by":"publisher","first-page":"16771","DOI":"10.3390\/ijms242316771","volume":"24","author":"MA Dom\u00ednguez-Cejudo","year":"2023","unstructured":"Dom\u00ednguez-Cejudo MA, Gil-Torralvo A, Cejuela M, et al. Targeting the Tumor Microenvironment in breast Cancer: prognostic and predictive significance and Therapeutic opportunities. Int J Mol Sci. 2023;24(23):16771.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4671_CR9","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cam4.2108","volume":"8","author":"Y Xiang","year":"2019","unstructured":"Xiang Y, Guo Z, Zhu P, et al. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science[J]. Cancer Med. 2019;8(5):1958\u201375.","journal-title":"Cancer Med"},{"issue":"7","key":"4671_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1142\/S0192415X21500737","volume":"49","author":"VW Ho","year":"2021","unstructured":"Ho VW, Tan HY, Guo W, et al. Efficacy and Safety of Chinese Herbal Medicine on treatment of breast Cancer: a Meta-analysis of Randomized Controlled Trials[J]. Am J Chin Med. 2021;49(7):1557\u201375.","journal-title":"Am J Chin Med"},{"issue":"12","key":"4671_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s11655-020-3422-y","volume":"27","author":"LN Yang","year":"2021","unstructured":"Yang LN, Wu ZL, Yang ZJ, et al. Exploring mechanism of Key Chinese Herbal Medicine on breast Cancer by Data Mining and Network Pharmacology Methods[J]. Chin J Integr Med. 2021;27(12):919\u201326.","journal-title":"Chin J Integr Med"},{"key":"4671_CR12","doi-asserted-by":"crossref","unstructured":"Zhao XY, Xu JY, Wang ZL, et al. Research progress on regulation of immune microenvironment of breast cancer by traditional Chinese medicine[J]. Microenviron Microecol Res. 2022;4(1):9\u201313.","DOI":"10.53388\/MMR2022002"},{"key":"4671_CR13","doi-asserted-by":"publisher","first-page":"113249","DOI":"10.1016\/j.jep.2020.113249","volume":"264","author":"Z Yang","year":"2020","unstructured":"Yang Z, Zhang Q, Yu L, et al. The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer[J]. J Ethnopharmacol. 2020;264:113249.","journal-title":"J Ethnopharmacol"},{"key":"4671_CR14","doi-asserted-by":"crossref","unstructured":"Jia XU, Chun-Lian WU. The research Progress of Shikonin Pharmacological Effect[J]. Pharm Biotechnol. 2015;22(1):87\u201390.","DOI":"10.1016\/j.phrs.2014.08.003"},{"key":"4671_CR15","doi-asserted-by":"crossref","unstructured":"Zhang X, Cui JH, Meng QQ, et al. Advance in anti-tumor mechanisms of Shikonin, Alkannin and their derivatives[J]. Mini Rev Med Chem. 2018;18(2):164\u201372.","DOI":"10.2174\/1389557517666170228114809"},{"key":"4671_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1360\/SSV-2021-0152","volume":"52","author":"X Wang","year":"2022","unstructured":"Wang X, Yang MK, Han HW, et al. Shikonins as natural products from traditional Chinese medicinal plants: their biosynthesis, genetic regulation, structural modifications, and pharmaceutical functions (in Chinese)[J]. Sci Sin Vitae. 2022;52:347\u201372.","journal-title":"Sci Sin Vitae"},{"key":"4671_CR17","doi-asserted-by":"crossref","unstructured":"Wang Q, Wang J, Wang J, et al. Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment[J]. Toxicol Res. 2021;10(6):1077\u201384.","DOI":"10.1093\/toxres\/tfab107"},{"issue":"1","key":"4671_CR18","first-page":"5","volume":"28","author":"W Feng","year":"2019","unstructured":"Feng W, Jianwen MA, Rao M. Effect and mechanism of Shikonin-Induced Necroptosis in Ovarian Cancer SKOV3 and A2780 Cells[J]. China Pharmaceuticals. 2019;28(1):5.","journal-title":"China Pharmaceuticals"},{"issue":"12","key":"4671_CR19","first-page":"7","volume":"47","author":"J Ma","year":"2018","unstructured":"Ma J, Feng W, Zhang L, et al. Mechanisms of Shikonin Inducing apoptosis in human non-small cell Lung Cancer A549 cells by promoting ROS Production[J]. J Med Res. 2018;47(12):7.","journal-title":"J Med Res"},{"issue":"009","key":"4671_CR20","first-page":"26","volume":"031","author":"Z Yang","year":"2018","unstructured":"Yang Z. Effects of Shikonin on immunologic function of the rats suffering Liver Cancer[J]. Western J Traditional Chin Med. 2018;031(009):26\u20139.","journal-title":"Western J Traditional Chin Med"},{"key":"4671_CR21","unstructured":"Guo XP, Zhang XY, Zhang SD. Clinical trial on the effects of shikonin mixture on later stage lung cancer (in Chinese)[J]. Zhong Xi Yi Jie He Za Zhi, 1991, 11(10):598\u20139, 580."},{"key":"4671_CR22","doi-asserted-by":"publisher","first-page":"38267","DOI":"10.1038\/srep38267","volume":"6","author":"W Liang","year":"2016","unstructured":"Liang W, Cai A, Chen G, et al. Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species[J]. Sci Rep. 2016;6:38267.","journal-title":"Sci Rep"},{"key":"4671_CR23","doi-asserted-by":"crossref","unstructured":"Han X, Kang KA, Piao MJ, et al. Shikonin exerts cytotoxic effects in human colon cancers by inducing apoptotic cell death via the endoplasmic reticulum and mitochondria-mediated Pathways[J]. Biomol Ther. 2019;27(1):41\u20137.","DOI":"10.4062\/biomolther.2018.047"},{"issue":"5","key":"4671_CR24","doi-asserted-by":"publisher","first-page":"e98624","DOI":"10.1371\/journal.pone.0098624","volume":"9","author":"LC Bailey-Downs","year":"2014","unstructured":"Bailey-Downs LC, Thorpe JE, Disch BC, et al. Development and characterization of a preclinical model of breast Cancer Lung Micrometastatic to Macrometastatic Progression[J]. PLoS ONE. 2014;9(5):e98624.","journal-title":"PLoS ONE"},{"issue":"8","key":"4671_CR25","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/ijc.32270","volume":"145","author":"JJ Arroyo-Crespo","year":"2019","unstructured":"Arroyo-Crespo JJ, Armi\u00f1\u00e1n A, Charbonnier D, et al. Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression[J]. Int J Cancer. 2019;145(8):2267\u201381.","journal-title":"Int J Cancer"},{"issue":"5","key":"4671_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.24272\/j.issn.2095-8137.2020.095","volume":"41","author":"L Zeng","year":"2020","unstructured":"Zeng L, Li W, Chen CS. Breast cancer animal models and applications[J]. Zool Res. 2020;41(5):477\u201394.","journal-title":"Zool Res"},{"issue":"9793","key":"4671_CR27","first-page":"102","volume":"72","author":"EA Rakha","year":"2020","unstructured":"Rakha EA, Pareja FG. New advances in molecular breast Cancer Pathology[J]. Sem Cancer Biol. 2020;72(9793):102\u201313.","journal-title":"Sem Cancer Biol"},{"issue":"23","key":"4671_CR28","doi-asserted-by":"publisher","first-page":"8264","DOI":"10.3390\/molecules27238264","volume":"27","author":"Z Guo","year":"2022","unstructured":"Guo Z, Sun L, Xia H, et al. Shikonin as a WT1 inhibitor promotes promyeloid leukemia cell differentiation. Molecules[J]. 2022;27(23):8264.","journal-title":"Molecules[J]"},{"issue":"1","key":"4671_CR29","first-page":"2662","volume":"47","author":"L Jia","year":"2019","unstructured":"Jia L, Zhu Z, Li H, et al. Shikonin inhibits proliferation, migration, invasion and promotes apoptosis in NCI-N87 cells via inhibition of PI3K\/AKT signal pathway[J]. Artif Cells. 2019;47(1):2662\u20139.","journal-title":"Artif Cells"},{"issue":"9","key":"4671_CR30","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.3390\/molecules27092747","volume":"27","author":"W Ji","year":"2022","unstructured":"Ji W, Sun X, Gao Y, et al. Natural compound shikonin is a novel PAK1 inhibitor and enhances efficacy of Chemotherapy against Pancreatic Cancer Cells[J]. Molecules. 2022;27(9):2747.","journal-title":"Molecules"},{"key":"4671_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.canlet.2019.04.033","volume":"459","author":"JC Boulos","year":"2019","unstructured":"Boulos JC, Rahama M, Hegazy M, et al. Shikonin derivatives for cancer prevention and therapy[J]. Cancer Lett. 2019;459:248\u201367.","journal-title":"Cancer Lett"},{"issue":"3","key":"4671_CR32","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ncrna.2024.02.007","volume":"9","author":"W Lou","year":"2024","unstructured":"Lou W, Xiao S, Lin K. Identification of a hypoxia-suppressed lncRNA RAMP2-AS1 in breast cancer[J]. Noncoding RNA Res. 2024;9(3):782\u201395.","journal-title":"Noncoding RNA Res"},{"key":"4671_CR33","doi-asserted-by":"crossref","unstructured":"Li MY, Mi C, Wang KS, et al. Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1\u03b1 signaling[J]. Chem Biol Interact. 2017;274:58\u201367.","DOI":"10.1016\/j.cbi.2017.06.029"},{"key":"4671_CR34","unstructured":"Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer[J]. Am Fam Physician. 2010;81(11):1339\u201346."},{"issue":"3","key":"4671_CR35","doi-asserted-by":"publisher","first-page":"e195410","DOI":"10.1001\/jamasurg.2019.5410","volume":"155","author":"M Golshan","year":"2020","unstructured":"Golshan M, Loibl S, Wong SM, et al. Breast conservation after Neoadjuvant Chemotherapy for Triple-negative breast Cancer: Surgical results from the BrighTNess Randomized Clinical Trial[J]. JAMA Surg. 2020;155(3):e195410.","journal-title":"JAMA Surg"},{"issue":"2","key":"4671_CR36","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3892\/ijo.2016.3558","volume":"49","author":"P-F Nesstor","year":"2016","unstructured":"Nesstor P-F. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines[J]. Int J Oncol. 2016;49(2):753\u201362.","journal-title":"Int J Oncol"},{"key":"4671_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ejpb.2022.07.006","volume":"177","author":"Q Liang","year":"2022","unstructured":"Liang Q, Lan Y, Li Y, et al. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy[J]. Eur J Pharm Biopharmaceutics: Official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e V. 2022;177:260\u201372.","journal-title":"Eur J Pharm Biopharmaceutics: Official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e V"},{"key":"4671_CR38","doi-asserted-by":"publisher","first-page":"153805","DOI":"10.1016\/j.phymed.2021.153805","volume":"94","author":"Q Sun","year":"2022","unstructured":"Sun Q, Gong T, Liu M, et al. Shikonin, a naphthalene ingredient: therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches[J]. Phytomedicine. 2022;94:153805.","journal-title":"Phytomedicine"},{"issue":"1\u20132","key":"4671_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1365\/s10337-010-1599-5","volume":"72","author":"L Sui, Huang","year":"2010","unstructured":"Sui, Huang L, et al. Simultaneous Quantitative Analysis of Shikonin and Deoxyshikonin in Rat plasma by Rapid LC\u2013ESI\u2013MS\u2013MS[J]. Chromatographia. 2010;72(1\u20132):63\u20139.","journal-title":"Chromatographia"},{"key":"4671_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bcp.2019.05.001","volume":"166","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen Zong-yue, Chen L, et al. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3\u03b2-regulated suppression of \u03b2-catenin signaling[J]. Biochem Pharmacol. 2019;166:33\u201345.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"4671_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11912-021-01033-x","volume":"23","author":"MJ Bueno","year":"2021","unstructured":"Bueno MJ, Ruiz-Sepulveda JL, Quintela-Fandino M. Mitochondrial inhibition: a treatment strategy in Cancer?[J]. Curr Oncol Rep. 2021;23(4):49.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"4671_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/1568009616666160216125833","volume":"17","author":"N Wang","year":"2017","unstructured":"Wang N, Wu Y, Bian J, et al. Current development of ROS-Modulating agents as Novel Antitumor Therapy[J]. Curr Cancer Drug Targets. 2017;17(2):122\u201336.","journal-title":"Curr Cancer Drug Targets"},{"issue":"12","key":"4671_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy[J]. Nat Rev Cancer. 2012;12(12):860\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4671_CR44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM. Role of Immunotherapy in Triple-negative breast Cancer[J]. J Natl Compr Canc Netw. 2020;18(4):479\u201389.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"4671_CR45","doi-asserted-by":"publisher","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","volume":"9","author":"H Nishikawa","year":"2021","unstructured":"Nishikawa H, Koyama S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies[J]. J Immunother Cancer. 2021;9(7):e002591.","journal-title":"J Immunother Cancer"},{"key":"4671_CR46","doi-asserted-by":"crossref","unstructured":"Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?[J]. Cancer Sci, 2019, 110(7).","DOI":"10.1111\/cas.14069"},{"issue":"6","key":"4671_CR47","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8\u2009+\u2009cytotoxic T lymphocytes in cancer immunotherapy: a review[J]. J Cell Physiol. 2019;234(6):8509\u201321.","journal-title":"J Cell Physiol"},{"key":"4671_CR48","doi-asserted-by":"publisher","first-page":"1263537","DOI":"10.3389\/fimmu.2023.1263537","volume":"14","author":"P Huang","year":"2023","unstructured":"Huang P, Zhou X, Zheng M, et al. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer[J]. Front Immunol. 2023;14:1263537.","journal-title":"Front Immunol"},{"key":"4671_CR49","doi-asserted-by":"publisher","first-page":"106831","DOI":"10.1016\/j.intimp.2020.106831","volume":"88","author":"J Guo","year":"2020","unstructured":"Guo J, Chen T, Ma Z, et al. Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF-\u03b2 receptor[J]. Int Immunopharmacol. 2020;88:106831.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"4671_CR50","first-page":"8509","volume":"234","author":"F Bagher","year":"2018","unstructured":"Bagher F. CD8\u2009+\u2009cytotoxic T lymphocytes in cancer immunotherapy: a review.[J]. J Cell Physiol. 2018;234(6):8509\u201321.","journal-title":"J Cell Physiol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-024-04671-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-024-04671-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-024-04671-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:02:16Z","timestamp":1731074536000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-024-04671-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4671"],"URL":"https:\/\/doi.org\/10.1186\/s12906-024-04671-3","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Ethics Committee of Sci-tech Industrial Park, Guangzhou University of Chinese Medicinee (Serial number: PZ22069) and carried out in accordance with the national rules, regulations of laboratory animal ethics and ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"389"}}